462 related articles for article (PubMed ID: 18600571)
1. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".
Snowden M; Green DV
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):553-8. PubMed ID: 18600571
[TBL] [Abstract][Full Text] [Related]
2. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
3. Affinity-based screening techniques for enhancing lead discovery.
Comess KM; Schurdak ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
[TBL] [Abstract][Full Text] [Related]
4. Integration of virtual and high-throughput screening.
Bajorath J
Nat Rev Drug Discov; 2002 Nov; 1(11):882-94. PubMed ID: 12415248
[TBL] [Abstract][Full Text] [Related]
5. A decade of fragment-based drug design: strategic advances and lessons learned.
Hajduk PJ; Greer J
Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
[TBL] [Abstract][Full Text] [Related]
6. A review of high throughput technology for the screening of natural products.
Mishra KP; Ganju L; Sairam M; Banerjee PK; Sawhney RC
Biomed Pharmacother; 2008 Feb; 62(2):94-8. PubMed ID: 17692498
[TBL] [Abstract][Full Text] [Related]
7. Which aspects of HTS are empirically correlated with downstream success?
Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
[TBL] [Abstract][Full Text] [Related]
8. Rational approaches to natural-product-based drug design.
Haustedt LO; Mang C; Siems K; Schiewe H
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
[TBL] [Abstract][Full Text] [Related]
9. The synergy between combinatorial chemistry and high-throughput screening.
Diller DJ
Curr Opin Drug Discov Devel; 2008 May; 11(3):346-55. PubMed ID: 18428088
[TBL] [Abstract][Full Text] [Related]
10. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads.
Langer T; Krovat EM
Curr Opin Drug Discov Devel; 2003 May; 6(3):370-6. PubMed ID: 12833670
[TBL] [Abstract][Full Text] [Related]
11. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.
Houston JG; Banks MN; Binnie A; Brenner S; O'Connell J; Petrillo EW
Drug Discov Today; 2008 Jan; 13(1-2):44-51. PubMed ID: 18190863
[TBL] [Abstract][Full Text] [Related]
12. Initial compound selection for sequential screening.
Young SS; Lam RL; Welch WJ
Curr Opin Drug Discov Devel; 2002 May; 5(3):422-7. PubMed ID: 12058618
[TBL] [Abstract][Full Text] [Related]
13. Prioritizing hits from phenotypic high-content screens.
Low J; Stancato L; Lee J; Sutherland JJ
Curr Opin Drug Discov Devel; 2008 May; 11(3):338-45. PubMed ID: 18428087
[TBL] [Abstract][Full Text] [Related]
14. Informatics and modeling challenges in fragment-based drug discovery.
Hubbard RE; Chen I; Davis B
Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
[TBL] [Abstract][Full Text] [Related]
15. Modeling the 3D structure of GPCRs: advances and application to drug discovery.
Becker OM; Shacham S; Marantz Y; Noiman S
Curr Opin Drug Discov Devel; 2003 May; 6(3):353-61. PubMed ID: 12833668
[TBL] [Abstract][Full Text] [Related]
16. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
Fischer HP
Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
[TBL] [Abstract][Full Text] [Related]
17. Hit discovery and hit-to-lead approaches.
Keseru GM; Makara GM
Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
[TBL] [Abstract][Full Text] [Related]
18. Enabling high-throughput discovery.
Vaschetto M; Weissbrod T; Bodle D; Güner O
Curr Opin Drug Discov Devel; 2003 May; 6(3):377-83. PubMed ID: 12833671
[TBL] [Abstract][Full Text] [Related]
19. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity.
Spencer RW
Biotechnol Bioeng; 1998; 61(1):61-7. PubMed ID: 10099497
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of natural products in drug discovery.
Koehn FE; Carter GT
Nat Rev Drug Discov; 2005 Mar; 4(3):206-20. PubMed ID: 15729362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
